7 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Genital Neoplasms, Female"
Show Display Options
Rank Status Study
1 Not yet recruiting Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer;   Recurrent Ovarian Cancer;   Recurrent Endometrial Cancer
Interventions: Drug: BKM120;   Drug: Nabpaclitaxel
2 Unknown  Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
Conditions: Endometrial Cancer;   Fatigue;   Neurotoxicity
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Radiation: brachytherapy;   Radiation: intensity-modulated radiation therapy;   Radiation: radiation therapy
3 Recruiting Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer (BRCA1, BRCA2);   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Recurrent Prostate Cancer;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Other: pharmacological study;   Other: laboratory biomarker analysis
4 Recruiting Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Sexuality and Reproductive Issues;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: cisplatin;   Drug: paclitaxel;   Drug: carboplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Procedure: quality-of-life assessment
5 Recruiting Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: paclitaxel;   Drug: docetaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
6 Recruiting Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
Conditions: Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Stage I Endometrial Carcinoma;   Stage II Endometrial Carcinoma;   Stage III Endometrial Carcinoma;   Stage IV Endometrial Carcinoma
Interventions: Drug: cisplatin;   Drug: paclitaxel;   Drug: carboplatin;   Radiation: brachytherapy
7 Recruiting Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer
Conditions: Ovarian Carcinosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Recurrent Uterine Sarcoma;   Stage I Uterine Sarcoma;   Stage IA Ovarian Epithelial Cancer;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Primary Peritoneal Cavity Cancer;   Stage II Uterine Sarcoma;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IV Uterine Sarcoma;   Uterine Carcinosarcoma
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: ifosfamide

Indicates status has not been verified in more than two years